Article
Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
Antiviral research - 1 Mar 2020
Takashita Emi, Daniels Rod S, Fujisaki Seiichiro, Gregory Vicki, Gubareva Larisa V, Huang Weiijuan, Hurt Aeron C, Lackenby Angie, Nguyen Ha T, Pereyaslov Dmitriy, Roe Merryn, Samaan Magdi, Subbarao Kanta, Tse Herman, Wang Dayan, Yen Hui-Ling, Zhang Wenqing, Meijer Adam
Abstract excerpt
The global analysis of neuraminidase inhibitor (NAI) susceptibility of influenza viruses has been conducted since the 2012-13 period. In 2018 a novel cap-dependent endonuclease inhibitor, baloxavir, that targets polymerase acidic subunit (PA) was approved for the treatment of influenza virus infection in Japan and the United States. For this annual report, the susceptibilities of influenza viruses to NAIs and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.